** Shares of drug developer Leap Therapeutics LPTX.O fall 67.1% to 74 cents premarket
** Co says it will not move forward with late-stage trials of its drug, sirexatamab, in patients with gastric cancer
** Says drug will show negative results for ongoing mid-stage trial's main goal of progression free survival when study completes
** Will explore partnership opportunities to test sirexatamab in combination with a type of cancer drugs called anti-PD-1 antibodies for treatment of gastric cancer and other diseases
** Up to last close, stock down 7.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。